
BioHarvest Sciences Inc.: financial statements
Price
$1.32
November 19, 2026Market cap $30M
What Ploutos Investor adds for BioHarvest Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+65.0% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $13M | $25M | $35M | +65.0% |
| Cost of revenue | $7.0M | $11M | $14M | +41.2% |
| Gross profit | $5.6M | $14M | $20M | +90.6% |
| Operating income | -$10.0M | -$7.0M | -$5.6M | |
| Net income | -$13M | -$13M | -$11M | |
| Earnings per share, basic | -$0.93 | -$0.80 | -$0.60 | |
| Margins | ||||
| Gross margin | 44.5% | 55.4% | 59.3% | |
| Operating margin | -78.6% | -27.7% | -16.2% | |
| Net margin | -99.1% | -51.3% | -32.3% | |
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
The full analysis
What do BioHarvest Sciences's filings show?
These are BioHarvest Sciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did BHST have in 2025?
BioHarvest Sciences had revenue of $35M and net income of -$11M in fiscal 2025, a net margin of -32.3%.
How much debt does BHST have?
On December 31, 2025 BioHarvest Sciences had total assets of $48M, debt of $149.0K and shareholders' equity of $25M.
How much free cash flow does BHST have?
In fiscal 2025 BioHarvest Sciences had cash from operations of -$7.2M and spent $2.4M on capital expenditure, leaving -$9.6M of free cash flow.
Where are the figures from?
From BioHarvest Sciences Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.